A Study of NST-6179 in Adult Subjects With Intestinal Failure-Associated Liver Disease (IFALD).
This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to
evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of
NST-6179 in adult subjects with intestinal failure-associated liver disease (IFALD) receivin...
Age: 18 years - 66+
Gender: All
Phase 2 Study to Assess the Safety, PK, and PD in SBS-IF Subjects
This is a randomized, double-blind, placebo-controlled, proof-of-concept (PoC), Phase 2 study
to assess the safety, PK, and PD of SC administration of HM15912 in adult subjects with
SBS-associated intestinal failure (SBS-IF).
Age: 18 years - 66+
Gender: All